The role of cetuximab in the treatment of patients with squamous cell carcinoma of the head and neck: resolution of the Expert Council

The role of cetuximab in the treatment of patients with squamous cell carcinoma of the head and neck: resolution of the Expert Council

.

Bibliographic Details
Format:	Article
Language:	Russian
Published:	ABV-press 2019-01-01
Series:	Опухоли головы и шеи
Online Access:	https://ogsh.abvpress.ru/jour/article/view/378

Similar Items

Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
by: J Greenhalgh, et al.
Published: (2009-10-01)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
by: Greg Knutzen, et al.
Published: (2015-11-01)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
by: Olivia Leblanc, et al.
Published: (2020-02-01)

Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck
by: S Griffin, et al.
Published: (2009-06-01)

Investigating the role of ADAM10 and ADAM17 in cetuximab resistance in head and neck squamous cell carcinoma
by: Kareemaghay, S
Published: (2014)

Matrisomal genes in squamous cell carcinoma of head and neck influence tumor cell motility and response to cetuximab treatment
by: Kah Yee Goh, et al.
Published: (2022-04-01)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Miren Taberna, et al.
Published: (2019-05-01)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
by: Tien-Hua Chen, et al.
Published: (2022-12-01)

Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
by: Chuan-Chien Yang, et al.
Published: (2022-05-01)

Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
by: Kunal eSaigal, et al.
Published: (2014-06-01)

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions
by: Joël Guigay, et al.
Published: (2019-08-01)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
by: Madelyn Espinosa-Cotton, et al.
Published: (2019-03-01)

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
by: Hannah Zaryouh, et al.
Published: (2021-09-01)

Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck
by: Jacques Bernier
Published: (2011-12-01)

Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck
by: Schmitz Sandra, et al.
Published: (2015-03-01)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Bruno Chauffert, et al.
Published: (2023-01-01)

FEASIBILITY OF INDUCTION DOCETAXEL, CISPLATIN, 5-FLUOROURACIL, CETUXIMAB (TPF-C) FOLLOWED BY CONCURRENT CETUXIMAB RADIOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
by: Nikolaos eCharalambakis, et al.
Published: (2013-01-01)

Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States
by: Himani Aggarwal, et al.
Published: (2020-06-01)

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
by: Thomas Chevalier, et al.
Published: (2021-06-01)

Prolonged cetuximab treatment promotes p27Kip1-mediated G1 arrest and autophagy in head and neck squamous cell carcinoma
by: Kohei Okuyama, et al.
Published: (2021-03-01)

Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck
by: Gabrielle van Caloen, et al.
Published: (2021-03-01)

The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma
by: Rin Liu, et al.
Published: (2021-12-01)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Shinsuke Suzuki, et al.
Published: (2021-10-01)

Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma
by: Won Jong Jin, et al.
Published: (2020-11-01)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
by: Juan A. Marín-Jiménez, et al.
Published: (2022-07-01)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
by: Tomohiro Enokida, et al.
Published: (2018-08-01)

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
by: Matthew Johnson, et al.
Published: (2022-06-01)

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review
by: Prakash Peddi, et al.
Published: (2015-01-01)

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review
by: Prakash Peddi, et al.
Published: (2015-01-01)

Taxanes in the Treatment of Head and Neck Squamous Cell Carcinoma
by: Ching-Yun Hsieh, et al.
Published: (2023-10-01)

Docetaxel in the treatment of squamous cell carcinoma of the head and neck
by: Alexander Rapidis, et al.
Published: (2008-11-01)

Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
by: Georgios Tsakonas, et al.
Published: (2020-10-01)

Eligibility criteria to cisplatin in head and neck squamous cell carcinoma: Egyptian expert opinion
by: Mohamed Abdulla, et al.
Published: (2023-01-01)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
by: Mohamedtaki A Tejani, et al.
Published: (2010-06-01)

Cetuximab: its unique place in head and neck cancer treatment
by: Specenier P, et al.
Published: (2013-04-01)

Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck
by: Petr Szturz, et al.
Published: (2016-08-01)

Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma
by: Fertig Elana J, et al.
Published: (2012-05-01)

Cetuximab Plus Chemotherapy versus Chemotherapy Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
by: Lang Y, et al.
Published: (2020-11-01)

RETRACTED: Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial
by: Yanqing Zheng PhD, et al.
Published: (2021-05-01)

Retracted: “Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial”
Published: (2023-07-01)